RxDoctor Payments Data

Jonathan Simon, MD

Internal Medicine · Ansonia, CTNPI 1073565511

Payments from drug & device makers

$1,291in general payments, 2019–2025

Across 74 payments — averaging $17.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$541
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$172
  • Pfizer$130
  • Ironwood Pharmaceuticals, Inc$71
  • Takeda Pharmaceuticals U.S.A., Inc.$61
  • Gilead$60
  • plus $255 from 12 others

What the payments were for

  • Consulting fees$111%
  • Food & beverage$1,26498%
  • Education$161%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,291 in reported general payments places this provider in the 80th percentile of 2,067 internal medicine providers in Connecticut.

See all internal medicine providers in Connecticut

Medicare billing

Part B allowed, 2024
$50,127
Medicare patients
215
Services billed
379

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RinvoqUpadacitinib22$152,807
XeljanzTofacitinib Citrate24$149,933
CreonLipase/Protease/Amylase43$120,634
LinzessLinaclotide138$97,504
XifaxanRifaximin11$28,878
Mesalamine48$18,445
NexiumEsomeprazole Magnesium26$14,391
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates219$13,717
Dexlansoprazole DrDexlansoprazole35$13,204
MovantikNaloxegol Oxalate16$9,289
VoqueznaVonoprazan Fumarate12$8,953
Omeprazole627$8,508
Mesalamine ErMesalamine14$6,877
Ondansetron Hcl264$5,539
Colestipol Hcl59$3,868

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRinvoq, Creon, Linzess$541$370,945203 claims
PfizerXeljanz$130$149,93324 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan, Plenvu$172$32,71038 claims
Redhill Biopharma Inc.Movantik$16$9,28916 claims
Braintree Laboratories, Inc.Sutab$18$2,11313 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,067 internal medicine providers in Connecticut.

Other internal medicine in Ansonia

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →